ANI Pharmaceuticals Beats, But Cortrophin Cut Drags Shares Down

ANI Pharmaceuticals(ANIP), ranking by market capitalization reported its fiscal 2026 Q2 earnings on Aug 07th, 2026.

The company delivered a significant beat on both top and bottom lines, with non-GAAP EPS of $2.21 surpassing estimates by $0.17 and revenue reaching $266.04 million, exceeding forecasts by $5.91 million. While full-year revenue guidance was reaffirmed in-line with expectations, the company lowered its specific Cortrophin Gel outlook, a move that overshadowed the strong quarterly results and contributed to negative market sentiment immediately following the release.

Revenue

The total revenue of ANI Pharmaceuticals increased by 25.9% to $266.04 million in 2026 Q2, up from $211.37 million in 2025 Q2.

Earnings/Net Income

ANI Pharmaceuticals's EPS rose 194.6% to $1.09 in 2026 Q2 from $0.37 in 2025 Q2, marking continued earnings growth. Meanwhile, the company's profitability strengthened with net income of $24.71 million in 2026 Q2, marking 189.1% growth from $8.55 million in 2025 Q2. Remarkably, in 2026 Q2, the company set a new record high for fiscal Q2 net income, the highest in over 20 years. The substantial double-digit percentage growth in both EPS and net income indicates highly effective cost management and strong operational leverage during the period.

Price Action

The stock price of ANI Pharmaceuticals has edged up 1.50% during the latest trading day, has edged down 1.25% during the most recent full trading week, and has dropped 7.69% month-to-date.

Post-Earnings Price Action Review

Following the earnings release, ANI Pharmaceuticals experienced immediate downward pressure, with shares falling approximately 7.6% in pre-market trading despite the company beating consensus estimates on both earnings per share and revenue. This decline was primarily driven by a downward revision in the full-year guidance for its key product, Cortrophin Gel, which was lowered to $520 million–$540 million from a previous range of $540 million–$575 million. Although the company reaffirmed its overall full-year revenue guidance of $1.08 billion to $1.14 billion and adjusted EBITDA expectations, the specific cut in Cortrophin outlook overshadowed the positive quarterly beat. Consequently, the stock has maintained a bearish trend, reflecting a 7.69% drop month-to-date as investors digested the mixed signals of strong current performance against cautious near-term product-specific guidance.

CEO Commentary

Nikhil Lalwani, President and Chief Executive Officer, highlighted ANI’s transformation into a leading rare disease company, driven by record Q2 revenues of $266 million and a 26% year-over-year growth. Cortrophin Gel revenues surged 43% to $117.1 million, fueled by strong momentum in existing specialties and a successful expansion into acute gouty arthritis flares with a 50% sales force increase. Lalwani noted that while insurance re-verification issues impacted Q1, they are resolved, allowing Q2 results to reflect pure organic growth. He emphasized the significant under-penetration of the ACTH market and the strategic shift toward rare diseases, which are expected to comprise nearly 60% of total revenues in 2026. The leadership outlook remains optimistic, citing positive leading indicators from the gout expansion and sustained demand in core specialties as key catalysts for future value creation.

Guidance

ANI reaffirms its full-year 2026 total net revenue guidance of $1.08 billion to $1.14 billion, representing 26% year-over-year growth, with rare disease as the primary driver. Cortrophin Gel revenue guidance is modestly revised to $520 million–$540 million, reflecting first-half results, with expectations of 50%–55% growth compared to 2025. ILUVIEN revenue guidance remains at $78 million–$83 million. Adjusted non-GAAP EBITDA is forecast to grow 27% year-over-year to $285 million–$300 million, while adjusted non-GAAP EPS is expected between $9.19 and $9.69. The company anticipates strong sequential revenue acceleration in Q4, driven by the full deployment of the gout-focused sales force and typical channel dynamics.

Additional News

In recent analyst developments, Wall Street Zen downgraded ANI Pharmaceuticals from a "strong-buy" to a "buy" rating, reflecting a cautious stance on near-term valuation despite solid fundamentals. Conversely, Weiss Ratings upgraded the stock from a "hold" to a "buy," highlighting improved risk-reward dynamics. Guggenheim maintained a "buy" rating with a $124 price target, while Canaccord Genuity initiated coverage with a "hold" rating and a $91 target. Zacks Research also lowered its rating to "hold," aligning with the current "Moderate Buy" consensus among analysts. These divergent views underscore market uncertainty regarding the impact of the Cortrophin Gel guidance cut. No significant M&A activity, executive changes, or dividend adjustments were reported in the immediate post-earnings window, with analyst sentiment remaining the primary driver of recent stock commentary.